Joon Won Yoon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joon Won Yoon has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- David Walterhouse
Division of Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois
2 shared publications - Elizabeth Hyjek
Department of Pathology/Hematopathology and Laboratory Medicine, Moffitt Cancer Center , Tampa, FL
2 shared publications - Karl-Frederic Vieux
Department of Biology, McGill University, Montreal, Quebec, Canada
2 shared publications Maria Proytcheva
2 shared publicationsMarilyn Lg Lamm
2 shared publications- Marisa Gallant
Department of Pediatrics University of North Carolina School of Medicine University of North Carolina at Chapel Hill Chapel Hill, NC United States
2 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Noncanonical Regulation of the Hedgehog Mediator GLI1 by c-MYC in Burkitt Lymphoma
PDF file - 1257K, Supplemental Figure 1. Exposure of Burkitt lymphoma cells to SHH, IHH, or cyclopamine. (A). We do not detect changes in cell viability by MTT assay following exposure of BL1648, BL2625, or BL1647 cells to SHH peptide, or (B) cell viability by MTT assay following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (C). We do not detect changes in cell proliferation by BrdU incorporation following exposure of BL1648, BL2725, or BL1647 cells to SHH peptide, or (D) cell proliferation by BrdU incorporation following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (E). We do not detect changes in apoptosis by caspase 3/7 assay following exposure of BL1648, BL2625, or BL1647 cells to SHH peptide, or (F) apoptosis by caspase 3/7 assay following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (G). GLI1 mRNA expression does not change by quantitative RT-PCR following treatment of BL1648 cells (black bars) or BL1596 cells (gray bars) with the HH pathway inhibitor cyclopamine (left panel) or the negative control tomatidine (right panel) for 24 hrs. The concentration (μM) of cyclopamine or tomatidine is shown on the x-axis. (H). Cell proliferation measured by BrdU assay does not generally change following treatment of BL1648 cells (black bars), BL1596 cells (gray bars), or BL2625 cells (white bars) with cyclopamine (left panel) or tomatidine (right panel; negative control). A statistically significant reduction in cell proliferation is seen for BL1596 cells using 10 μM cyclopamine (* indicates p<0.05). A statistically significant increase in cell proliferation is seen for BL2625 cells using 10 μM tomatidine. (I). Apoptosis measured by caspase3/7 assay does not change following treatment of BL1648 cells (black bars), BL1596 cells (gray bars), or BL2625 cells (white bars) with cyclopamine (left panel) or tomatidine (right panel; negative control). A statistically significant decrease in caspase activity is seen in BL1648 cells treated with 1 μM tomatidine.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Noncanonical Regulation of the Hedgehog Mediator GLI1 by c-MYC in Burkitt Lymphoma
PDF file - 1257K, Supplemental Figure 1. Exposure of Burkitt lymphoma cells to SHH, IHH, or cyclopamine. (A). We do not detect changes in cell viability by MTT assay following exposure of BL1648, BL2625, or BL1647 cells to SHH peptide, or (B) cell viability by MTT assay following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (C). We do not detect changes in cell proliferation by BrdU incorporation following exposure of BL1648, BL2725, or BL1647 cells to SHH peptide, or (D) cell proliferation by BrdU incorporation following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (E). We do not detect changes in apoptosis by caspase 3/7 assay following exposure of BL1648, BL2625, or BL1647 cells to SHH peptide, or (F) apoptosis by caspase 3/7 assay following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (G). GLI1 mRNA expression does not change by quantitative RT-PCR following treatment of BL1648 cells (black bars) or BL1596 cells (gray bars) with the HH pathway inhibitor cyclopamine (left panel) or the negative control tomatidine (right panel) for 24 hrs. The concentration (μM) of cyclopamine or tomatidine is shown on the x-axis. (H). Cell proliferation measured by BrdU assay does not generally change following treatment of BL1648 cells (black bars), BL1596 cells (gray bars), or BL2625 cells (white bars) with cyclopamine (left panel) or tomatidine (right panel; negative control). A statistically significant reduction in cell proliferation is seen for BL1596 cells using 10 μM cyclopamine (* indicates p<0.05). A statistically significant increase in cell proliferation is seen for BL2625 cells using 10 μM tomatidine. (I). Apoptosis measured by caspase3/7 assay does not change following treatment of BL1648 cells (black bars), BL1596 cells (gray bars), or BL2625 cells (white bars) with cyclopamine (left panel) or tomatidine (right panel; negative control). A statistically significant decrease in caspase activity is seen in BL1648 cells treated with 1 μM tomatidine.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Noncanonical Regulation of the Hedgehog Mediator GLI1 by c-MYC in Burkitt Lymphoma
PDF file - 1257K, Supplemental Figure 1. Exposure of Burkitt lymphoma cells to SHH, IHH, or cyclopamine. (A). We do not detect changes in cell viability by MTT assay following exposure of BL1648, BL2625, or BL1647 cells to SHH peptide, or (B) cell viability by MTT assay following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (C). We do not detect changes in cell proliferation by BrdU incorporation following exposure of BL1648, BL2725, or BL1647 cells to SHH peptide, or (D) cell proliferation by BrdU incorporation following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (E). We do not detect changes in apoptosis by caspase 3/7 assay following exposure of BL1648, BL2625, or BL1647 cells to SHH peptide, or (F) apoptosis by caspase 3/7 assay following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (G). GLI1 mRNA expression does not change by quantitative RT-PCR following treatment of BL1648 cells (black bars) or BL1596 cells (gray bars) with the HH pathway inhibitor cyclopamine (left panel) or the negative control tomatidine (right panel) for 24 hrs. The concentration (μM) of cyclopamine or tomatidine is shown on the x-axis. (H). Cell proliferation measured by BrdU assay does not generally change following treatment of BL1648 cells (black bars), BL1596 cells (gray bars), or BL2625 cells (white bars) with cyclopamine (left panel) or tomatidine (right panel; negative control). A statistically significant reduction in cell proliferation is seen for BL1596 cells using 10 μM cyclopamine (* indicates p<0.05). A statistically significant increase in cell proliferation is seen for BL2625 cells using 10 μM tomatidine. (I). Apoptosis measured by caspase3/7 assay does not change following treatment of BL1648 cells (black bars), BL1596 cells (gray bars), or BL2625 cells (white bars) with cyclopamine (left panel) or tomatidine (right panel; negative control). A statistically significant decrease in caspase activity is seen in BL1648 cells treated with 1 μM tomatidine.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Noncanonical Regulation of the Hedgehog Mediator GLI1 by c-MYC in Burkitt Lymphoma
PDF file - 1257K, Supplemental Figure 1. Exposure of Burkitt lymphoma cells to SHH, IHH, or cyclopamine. (A). We do not detect changes in cell viability by MTT assay following exposure of BL1648, BL2625, or BL1647 cells to SHH peptide, or (B) cell viability by MTT assay following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (C). We do not detect changes in cell proliferation by BrdU incorporation following exposure of BL1648, BL2725, or BL1647 cells to SHH peptide, or (D) cell proliferation by BrdU incorporation following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (E). We do not detect changes in apoptosis by caspase 3/7 assay following exposure of BL1648, BL2625, or BL1647 cells to SHH peptide, or (F) apoptosis by caspase 3/7 assay following exposure of BL1648, BL2625, BL1647, or BL1596 cells to IHH peptide. (G). GLI1 mRNA expression does not change by quantitative RT-PCR following treatment of BL1648 cells (black bars) or BL1596 cells (gray bars) with the HH pathway inhibitor cyclopamine (left panel) or the negative control tomatidine (right panel) for 24 hrs. The concentration (μM) of cyclopamine or tomatidine is shown on the x-axis. (H). Cell proliferation measured by BrdU assay does not generally change following treatment of BL1648 cells (black bars), BL1596 cells (gray bars), or BL2625 cells (white bars) with cyclopamine (left panel) or tomatidine (right panel; negative control). A statistically significant reduction in cell proliferation is seen for BL1596 cells using 10 μM cyclopamine (* indicates p<0.05). A statistically significant increase in cell proliferation is seen for BL2625 cells using 10 μM tomatidine. (I). Apoptosis measured by caspase3/7 assay does not change following treatment of BL1648 cells (black bars), BL1596 cells (gray bars), or BL2625 cells (white bars) with cyclopamine (left panel) or tomatidine (right panel; negative control). A statistically significant decrease in caspase activity is seen in BL1648 cells treated with 1 μM tomatidine.
- 1 August 2017
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 60 (8) , 411-415
Novel missense loss-of-function mutations of WNT1 in an autosomal recessive Osteogenesis imperfecta patient
- 1 August 2017
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 60 (8) , 411-415
Novel missense loss-of-function mutations of WNT1 in an autosomal recessive Osteogenesis imperfecta patient
- Open Access
- 1 January 2017
- Published by The Company of Biologists in Development
- Vol. 144 (11) , 2082-2091
Sonic Hedgehog regulation of Foxf2 promotes cranial neural crest mesenchyme proliferation and is disrupted in cleft lip morphogenesis
Cleft lip is one of the most common human birth defects, yet our understanding of the mechanisms that regulate lip morphogenesis is limited. Here, we show that Sonic Hedgehog (Shh)-induced proliferation of cranial neural crest cell (cNCC) mesenchyme is required for upper lip closure. Gene expression profiling revealed a subset of Forkhead box (Fox) genes regulated by Shh signaling during lip morphogenesis. During cleft pathogenesis, reduced proliferation in the medial nasal process mesenchyme paralleled the domain of reduced Foxf2 and Gli1 expression. SHH ligand induction of Foxf2 expression was dependent upon Shh pathway effectors in cNCCs, while a functional GLI binding site was identified downstream of Foxf2. Consistent with the cellular mechanism demonstrated for cleft lip pathogenesis, we found that either SHH ligand addition or FOXF2 overexpression is sufficient to induce cNCC proliferation. Finally, analysis of a large multi-ethnic human population with cleft lip identified clusters of single-nucleotide polymorphisms in FOXF2. These data suggest that direct targeting of Foxf2 by Shh signaling drives cNCC mesenchyme proliferation during upper lip morphogenesis, and that disruption of this sequence results in cleft lip.
- 1 January 2017
- Published by The Company of Biologists in Development
- Vol. 144 (11) , 2082-2091
Open AccessSonic Hedgehog regulation of Foxf2 promotes cranial neural crest mesenchyme proliferation and is disrupted in cleft lip morphogenesis
Cleft lip is one of the most common human birth defects, yet our understanding of the mechanisms that regulate lip morphogenesis is limited. Here, we show that Sonic Hedgehog (Shh)-induced proliferation of cranial neural crest cell (cNCC) mesenchyme is required for upper lip closure. Gene expression profiling revealed a subset of Forkhead box (Fox) genes regulated by Shh signaling during lip morphogenesis. During cleft pathogenesis, reduced proliferation in the medial nasal process mesenchyme paralleled the domain of reduced Foxf2 and Gli1 expression. SHH ligand induction of Foxf2 expression was dependent upon Shh pathway effectors in cNCCs, while a functional GLI binding site was identified downstream of Foxf2. Consistent with the cellular mechanism demonstrated for cleft lip pathogenesis, we found that either SHH ligand addition or FOXF2 overexpression is sufficient to induce cNCC proliferation. Finally, analysis of a large multi-ethnic human population with cleft lip identified clusters of single-nucleotide polymorphisms in FOXF2. These data suggest that direct targeting of Foxf2 by Shh signaling drives cNCC mesenchyme proliferation during upper lip morphogenesis, and that disruption of this sequence results in cleft lip.